Development of a Prediction Score for the Occurrence of Death or Lung Transplantation in Patients With Emphysema Secondary to Alpha-1-anti-tripsin Deficiency

Summary

Emphysema linked to alpha-1-antitrypsin deficiency (DAAT): towards a better prediction of risks Emphysema caused by alpha-1-antitrypsin deficiency (DAAT) is a rare genetic disorder that can lead to serious complications, such as the need for a lung transplant or death, affecting up to 15% of patients. The only specific treatment available is a weekly infusion of alpha-1-antitrypsin (IV-AAT), an expensive and burdensome therapy. Currently, there is no reliable model to predict the course of the disease in these patients. Our study, conducted in several French hospitals, aims to develop a prediction tool combining clinical, biological, functional data and advanced medical image analysis (lung CT). This model will make it possible to identify the most at-risk patients, in order to better adapt their care, anticipate transplant needs and avoid unnecessary treatments for low-risk patients. Ultimately, this approach could also improve access to care for patients who need it most, while optimizing health system resources.

Eligibility

1. Inclusion criteria:

   * diagnosed between 2010 and 2025
   * in the pulmonology department
   * diagnosis of emphysema and COPD secondary to alpha-1 antitrypsin deficiency ZZ, Znull, ZMalton, Z and rare mutations,
   * emphysema according to the initial thoracic CT scan (+/- 12 months after diagnosis).
2. Exclusion criteria:

   * Age \<18 years
   * Patient opposed to the use of their data for research purposes
   * Patient deprived of liberty by judicial decision
   * Patient not affiliated with a social security scheme
   * no CT scan available
   * no lung function test available the year around CT scan

Conditions7

Browse More Trials